Sung Hee Youn1, Seung Soon Lee1, Sukyeon Kim1, Jeong-A Lee1, Bum Joon Kim1, Jounghee Kim2, Hye-Kyung Han2, Jae-Seok Kim3. 1. Division of Infectious Diseases, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea. 2. Department of Pharmacy, Hallym University Sacred Heart Hospital, Anyang, Korea. 3. Department of Laboratory Medicine, Hallym University Kangdong Sacred Heart Hospital, Seoul, Korea.
Abstract
BACKGROUND/AIMS: Intranasal mupirocin and chlorhexidine bathing are candidate strategies to prevent healthcare-associated infections caused by methicillin-resistant Staphylococcus aureus (MRSA). In Korea, intranasal mupirocin is not available, and mupirocin ointment, an over-the-counter drug, has been used indiscriminately. Furthermore, because it is covered by health insurance, mupirocin is easy to prescribe within hospitals. METHODS: We performed a mupirocin drug utilization review (DUR) within Hallym University Sacred Heart Hospital. Annual use of mupirocin was investigated between 2003 and 2013, and monthly consumption of mupirocin was assessed during the final 2-year period. The DUR focused on August 2012, the period of highest use of mupirocin. Also, we investigated trends in mupirocin resistance in MRSA between 2011 and 2013. RESULTS: Annual consumption of mupirocin increased from 3,529 tubes in 2003 to 6,475 tubes in 2013. During August 2012, 817 tubes were prescribed to 598 patients; of these, 84.9% were prescribed to outpatients, and 77.6% at the dermatology department. The most common indication was prevention of skin infections (84.9%), and the ointment was combined with systemic antibiotics in 62.9% of cases. The average duration of systemic antibiotic administration was about 7.8 days. The rate of low-level mupirocin resistance in MRSA increased from 8.0% to 22.0%, and that of high-level mupirocin resistance increased from about 4.0% to about 7.5%. CONCLUSIONS: Inappropriate use of mupirocin is prevalent. Considering the increase in resistance and the future application of intranasal mupirocin, prophylactic use of mupirocin in dermatology departments should be reconsidered.
BACKGROUND/AIMS: Intranasal mupirocin and chlorhexidine bathing are candidate strategies to prevent healthcare-associated infections caused by methicillin-resistant Staphylococcus aureus (MRSA). In Korea, intranasal mupirocin is not available, and mupirocin ointment, an over-the-counter drug, has been used indiscriminately. Furthermore, because it is covered by health insurance, mupirocin is easy to prescribe within hospitals. METHODS: We performed a mupirocin drug utilization review (DUR) within Hallym University Sacred Heart Hospital. Annual use of mupirocin was investigated between 2003 and 2013, and monthly consumption of mupirocin was assessed during the final 2-year period. The DUR focused on August 2012, the period of highest use of mupirocin. Also, we investigated trends in mupirocin resistance in MRSA between 2011 and 2013. RESULTS: Annual consumption of mupirocin increased from 3,529 tubes in 2003 to 6,475 tubes in 2013. During August 2012, 817 tubes were prescribed to 598 patients; of these, 84.9% were prescribed to outpatients, and 77.6% at the dermatology department. The most common indication was prevention of skin infections (84.9%), and the ointment was combined with systemic antibiotics in 62.9% of cases. The average duration of systemic antibiotic administration was about 7.8 days. The rate of low-level mupirocin resistance in MRSA increased from 8.0% to 22.0%, and that of high-level mupirocin resistance increased from about 4.0% to about 7.5%. CONCLUSIONS: Inappropriate use of mupirocin is prevalent. Considering the increase in resistance and the future application of intranasal mupirocin, prophylactic use of mupirocin in dermatology departments should be reconsidered.
Entities:
Keywords:
Drug resistance, bacterial; Drug utilization review; Methicillin-resistant Staphylococcus aureus; Mupirocin
Authors: A S Lee; M Macedo-Vinas; P François; G Renzi; N Vernaz; J Schrenzel; D Pittet; S Harbarth Journal: J Hosp Infect Date: 2011-01-26 Impact factor: 3.926
Authors: Glenn Ridenour; Russell Lampen; Jeff Federspiel; Steve Kritchevsky; Edward Wong; Michael Climo Journal: Infect Control Hosp Epidemiol Date: 2007-08-01 Impact factor: 3.254
Authors: Jin Ah Yang; Dae Won Park; Jang Wook Sohn; In Seok Yang; Kyung Hyun Kim; Min Ja Kim Journal: J Korean Med Sci Date: 2006-10 Impact factor: 2.153
Authors: Hong Bin Kim; Hee-Chang Jang; Hee Jung Nam; Yeong Seon Lee; Bong Su Kim; Wan Beom Park; Ki Deok Lee; Young Joo Choi; Sang Won Park; Myoung-Don Oh; Eui-Chong Kim; Kang Won Choe Journal: Antimicrob Agents Chemother Date: 2004-04 Impact factor: 5.191